ConductScience.org, home

Paper9748116

The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.

Frei E and 4 others. Clin Cancer Res, 1998. Cited by 78 papers, by iCite.

Cite this record

ConductScience Library. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Papers, record 9748116. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9748116

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.
PubMed
Journal
Clin Cancer Res
PubMed
Year
1998
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
78
iCite
Relative citation ratio, by iCite
1.76
iCite
Revised in PubMed
2007-11-15
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Frei E 3rdE
2Elias AA
3Wheeler CC
4Richardson PP
5Hryniuk WW

Source PubMed

Download CSV of authors

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
NeoplasmsMajor topic
Clinical Trials as Topic
Dose-Response Relationship, Drug
Humans

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT05381038Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AIBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 78 citations.

PMIDTitleJournalYearIn PapersSource
41140641Stackelberg Evolutionary Games of Cancer Treatment: What Treatment Strategy to Choose if Cancer Can be Stabilized?Dyn Games Appl2025https://conductscience.org/library/papers/41140641PubMed
37446271Propranolol, Promising Chemosensitizer and Candidate for the Combined Therapy through Disruption of Tumor Microenvironment Homeostasis by Decreasing the Level of Carbonic Anhydrase IX.Int J Mol Sci2023https://conductscience.org/library/papers/37446271PubMed
36221000Mitigating acute chemotherapy-associated adverse events in patients with cancer.Nat Rev Clin Oncol2022https://conductscience.org/library/papers/36221000PubMed
35440517Modulation of Reactive Oxygen Species to Overcome 5-Fluorouracil Resistance.Biomol Ther (Seoul)2022https://conductscience.org/library/papers/35440517PubMed
35340557Management of chemotherapy dose intensity for metastatic colorectal cancer.Oncol Lett2022https://conductscience.org/library/papers/35340557PubMed
34741706In vitro evaluation of the anticancer activity of barbituric/thiobarbituric acid-based chromene derivatives.Mol Biol Rep2021https://conductscience.org/library/papers/34741706PubMed
31799475Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials.Contemp Clin Trials Commun2019https://conductscience.org/library/papers/31799475PubMed
31742555A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.Elife2019https://conductscience.org/library/papers/31742555PubMed
30381824Detection of circulating microRNAs with Ago2 complexes to monitor the tumor dynamics of colorectal cancer patients during chemotherapy.Int J Cancer2019https://conductscience.org/library/papers/30381824PubMed
29114963Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials.Cancer Sci2018https://conductscience.org/library/papers/29114963PubMed
28440955Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.Cancer2017https://conductscience.org/library/papers/28440955PubMed
26912903Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer.Sci Transl Med2016https://conductscience.org/library/papers/26912903PubMed
25895611Clinical management of breast cancer heterogeneity.Nat Rev Clin Oncol2015https://conductscience.org/library/papers/25895611PubMed
25795051Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation.Drug Deliv Transl Res2015https://conductscience.org/library/papers/25795051PubMed
25755993Development of oxaliplatin encapsulated in magnetic nanocarriers of pectin as a potential targeted drug delivery for cancer therapy.Results Pharma Sci2012https://conductscience.org/library/papers/25755993PubMed
24512451Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma.J Vet Intern Med2014https://conductscience.org/library/papers/24512451PubMed
24386166Peptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal models.PLoS One2013https://conductscience.org/library/papers/24386166PubMed
23682309Engineering and Applications of DNA-Grafting Polymer Materials.Chem Sci2013https://conductscience.org/library/papers/23682309PubMed
23251029Defining principles of combination drug mechanisms of action.Proc Natl Acad Sci U S A2013https://conductscience.org/library/papers/23251029PubMed
20443090Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivo.AAPS PharmSciTech2010https://conductscience.org/library/papers/20443090PubMed

See all 25 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9748116

GET https://conductscience.org/api/papers/v1/9748116/cited_by?page=2